Table 1 Baseline characteristics of CHD cases and controls in the NHS and HPFS studies1
|  | case (n = 101) | control (n = 101) | P-values2 |
|---|---|---|---|
Age (yr)a | 56.7 ± 7.9 | 56.8 ± 7.8 | - |
Female (%)a | 50.5 | 50.5 | - |
Smoking, %a | |||
 Past | 32.7 | 33.6 | - |
 Current | 13.8 | 12.9 | - |
BMI (kg/m2) | 26.2 ± 4.7 | 25.7 ± 3.8 | 0.48 |
Physical activity (MET/wk) | 26.6 ± 37.8 | 25.6 ± 23.9 | 0.83 |
Alcohol intake (g/d) | 2.4 ± 1.0 | 2.4 ± 1.0 | 0.83 |
AHEI | 46.8 ± 9.4 | 48.3 ± 10.5 | 0.27 |
Fasting, % | 62.3 | 58.6 | 0.04 |
Using of cholesterol lowering medication, % | 8.9 | 3.0 |  < 0.001 |
Aspirin use, % | 39.6 | 36.6 | 0.02 |
Family history of MI, % | 44.6 | 18.8 | 0.001 |
History of hypercholesterolemia, % | 56.6 | 35.7 | 0.47 |
History of hypertension, % | 47.6 | 24.9 | 0.01 |
History of diabetes, % | 14.0 | 2.0 |  < 0.001 |
PFAS (ng/mL) | |||
Total PFOS | 36.8 ± 19.8 | 34.0 ± 15.0 | 0.26 |
brPFOS | 9.5 ± 4.8 | 8.6 ± 4.0 | 0.13 |
nPFOS | 27.2 ± 15.5 | 25.4 ± 11.5 | 0.33 |
PFHxS | 4.7 ± 5.1 | 6.2 ± 13.9 | 0.32 |
PFOA | 5.6 ± 4.7 | 5.7 ± 5.8 | 0.96 |
PFNA | 0.8 ± 0.5 | 0.9 ± 0.6 | 0.74 |
PFDA | 0.2 ± 0.2 | 0.3 ± 0.2 | 0.89 |
Blood lipids (mg/dL) | |||
 TC | 223.0 ± 40.7 | 207.6 ± 34.6 | 0.005 |
 TG | 172.4 ± 120.3 | 129.5 ± 76.3 | 0.004 |
 HDL-C | 47.1 ± 16.2 | 52.1 ± 13.5 | 0.02 |
 LDL-C | 137.4 ± 37.4 | 124.5 ± 31.2 | 0.01 |
CRP (mg/L) | 0.4 ± 0.5 | 0.3 ± 0.5 | 0.18 |